![Analysis of Mass Spec data (dashed-line) of fractions stained with Vimentin Anti-Human MS-QAVA™ monoclonal antibody [Clone: VM452] (solid-line), reveals that less than 4.2% of signal is attributable to non-specific binding of anti-Vimentin [Clone: VM452 ] to targets other than VIM protein. Even frequently cited antibodies have much greater non-specific interactions, averaging over 30%. Data in image is from analysis in Jurkat, U202 and HeLa cells.](https://cdn-enquirebio.pressidium.com/wp-content/uploads/2017/10/enQuire-Bio-7431-MSM1-P1-anti-Vimentin-Anti-Human-antibody.png "Vimentin Anti-Human Antibody Mass Spec Validation Data")
PDF DatasheetHuman, Bovine, Canine, Feline, Pig, Goat, and Chicken Anti-Vimentin Anti-Human Antibody Product Attributes
Vimentin Anti-Human Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Variations in Vimentin Anti-Human antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in lymphoid tissue in appendix, hematopoietic cells in the bone marrow, adipocytes in breast, endothelial cells in the cerebral cortex and colon, glandular cells in the epididymis and fallopian tube, cells in the glomeruli in kidney, macrophages in lung, pneumocytes in lung, germinal center cells in the lymph node, non-germinal center cells in the lymph node, ovarian stroma cells in the ovary, glandular cells in the seminal vesicle, fibroblasts in skin, Langerhans in skin, melanocytes in skin, adipocytes in mesenchymal tissue, fibroblasts in mesenchymal tissue, peripheral nerve in mesenchymal tissue, cells in the red pulp in spleen, cells in the seminiferous ducts in testis, Leydig cells in the testis, glandular cells in the thyroid gland, germinal center cells in the tonsil and non-germinal center cells in the tonsil. More moderate antibody staining intensity was present in lymphoid tissue in appendix, hematopoietic cells in the bone marrow, adipocytes in breast, endothelial cells in the cerebral cortex and colon, glandular cells in the epididymis and fallopian tube, cells in the glomeruli in kidney, macrophages in lung, pneumocytes in lung, germinal center cells in the lymph node, non-germinal center cells in the lymph node, ovarian stroma cells in the ovary, glandular cells in the seminal vesicle, fibroblasts in skin, Langerhans in skin, melanocytes in skin, adipocytes in mesenchymal tissue, fibroblasts in mesenchymal tissue, peripheral nerve in mesenchymal tissue, cells in the red pulp in spleen, cells in the seminiferous ducts in testis, Leydig cells in the testis, glandular cells in the thyroid gland, germinal center cells in the tonsil and non-germinal center cells in the tonsil. Low, but measureable presence of Vimentin Anti-Human could be seen inglandular cells in the adrenal gland, respiratory epithelial cells in the bronchus, glial cells in the cerebral cortex, cells in the endometrial stroma in endometrium, glial cells in the hippocampus, bile duct cells in the liver, respiratory epithelial cells in the nasopharynx, follicle cells in the ovary, decidual cells in the placenta and squamous epithelial cells in the vagina. We were unable to detect Vimentin Anti-Human in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Type:
Tissues from cancer patients, for instance, have their own distinct pattern of Vimentin Anti-Human expression as measured by anti-Vimentin Anti-Human antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | + | – | ++ | – | ++ | ++ | ++ | +++ | +++ | + | ++ | – | +++ | ++ | ++ | ++ | +++ | ++ |
| VIM Variability | + | + | ++ | ++ | ++ | ++ | ++ | ++ | + | ++ | + | ++ | + | ++ | + | ++ | + | ++ | + | ++ |
| Vimentin Anti-Human General Information | |
|---|---|
| Alternate Names | |
| Vimentin, Anti-Vimentin | |
| Molecular Weight | |
| 57-60kDa | |
| Chromosomal Location | |
| 10p12.33 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | VIM |
| Entrez Gene ID | 7431 |
| Ensemble Gene ID | ENSG00000026025 |
| RefSeq Protein Accession(s) | NP_003371, XP_006717563 |
| RefSeq mRNA Accession(s) | XM_006717500, NM_003380 |
| RefSeq Genomic Accession(s) | NC_018921, NC_000010, NG_012413 |
| UniProt ID(s) | P08670, V9HWE1 |
| UniGene ID(s) | P08670, V9HWE1 |
| HGNC ID(s) | 12692 |
| Cosmic ID(s) | VIM |
| KEGG Gene ID(s) | hsa:7431 |
| PharmGKB ID(s) | PA37311 |
| General Description of Vimentin Anti-Human. | |
| This MAb reacts with a 58kDa protein identified as vimentin. It shows no cross-reaction with other closely related intermediate filament proteins (IFPs) such as desmin, keratin, neurofilament, and glial fibrillary acid protein.Anti-vimentin alone is of limited value as a diagnostic tool, however, when used in panels with other antibodies, it is useful for the sub-classification of a given tumor. Expression of vimentin, when used in conjunction with anti-keratin, is helpful when distinguishing melanomas from undifferentiated carcinomas and large cell lymphomas. All melanomas and Schwannomas react strongly with anti-vimentin. It labels a variety of mesenchymal cells, including melanocytes, lymphocytes, endothelial cells, and fibroblasts. Non-reactivity of anti-vimentin is often considered more useful than its positive reactivity, since there are a few tumors that do not contain vimentin, e.g. hepatoma and seminoma. Anti-vimentin is also useful as a tissue process control reagent. | |
There are no reviews yet.